Opinion
Video
Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
Panelists discuss how managed care organizations can improve Alzheimer diagnostic test access while navigating complex coverage challenges for amyloid-targeting therapies across traditional Medicare (with restrictive NCDs), Medicare Advantage plans, private insurance, and younger patients who face categorical exclusions despite clinical need.
Video content above is prompted by the following:
4. How can managed care organizations ensure that appropriate patients have access to diagnostic tests for Alzheimer disease?
5. What are some of the challenges with the current coverage landscape for amyloid-targeting therapies?
a. Expectation to discuss coverage for Medicare vs patients with Medicare Advantage vs private insurance plans as well as patients younger than 65 years.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
